Explore the groundbreaking Phase I clinical trial of (131)I-labeled CIGB-M3 antibody fragment for targeted colorectal cancer treatment using radioimmunotheranostics.
Discover how bispecific antisense oligonucleotides targeting Bcl-2 and Bcl-xL proteins are revolutionizing cancer therapy by flipping cancer's apoptotic switch.